Predict your next investment

CancerIQ company logo
INTERNET | Internet Software & Services / Healthcare
canceriq.com

See what CB Insights has to offer

Founded Year

2013

Stage

Series A - II | Alive

Total Raised

$6.52M

Last Raised

$4.8M | 1 yr ago

About CancerIQ

CancerIQ operates a web-based big data application that converts oncology data stored in unstructured enterprise data warehouses into research-quality data for secondary use. It is a proven data management and data sharing tool for translational research and contains a unique data model that integrates genomics into clinical practice.

CancerIQ Headquarter Location

515 N. State Suite 1075

Chicago, Illinois, 60654,

United States

312-761-3360

Latest CancerIQ News

Adventist Health, OSF HealthCare Use CancerIQ to Prioritize Patients for Preventive Cancer Screenings

Apr 19, 2021

What You Should Know: – As the nation braces for a rise in advanced stage cancer diagnoses due to the COVID-19 pandemic, two leading health systems –  Adventist Health  and  OSF HealthCare  – are using  CancerIQ’s  precision prevention platform and telehealth to equitably prioritize high-risk patients for screening and identify cancer in its earliest stages. – Clinicians to present at National Consortium of Breast Center conference on expanding access to precision cancer prevention, addressing SDOH, and the future of virtual cancer care. – These sessions will explore how breast centers responded to the pandemic, expediting the adoption of virtual care to better serve high-risk patients who may have been missed otherwise due to COVID-19 restrictions or other barriers. Clinicians will share new data, real-life patient stories, and lessons learned to help illuminate strategies for a more equitable, value-based future. – Access to risk assessments and genetic testing and counseling expands when these services are offered virtually. It gives people the flexibility to complete assessments and testing at home, which reduces barriers like transportation and time availability. It also improves quality because people have more time to put thought into their responses and call family members to confirm information, leading to a more accurate picture of their risk. It also helps health systems facing a shortage of genetic counselors by enabling nurse practitioners to champion the process.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CancerIQ

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CancerIQ is included in 4 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,256 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

1,849 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

CancerIQ Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CancerIQ Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.